Hoe verhoudt DOA's PS Ratio zich tot zijn concurrenten?

DOA is een goede waarde op basis van zijn Price-To-Sales Ratio (9.1x) vergeleken met het gemiddelde van gelijken (16.1x).

Hoe verhoudt DOA's PS Ratio zich tot andere bedrijven in de DE Biotechs industrie?

DOA is duur op basis van de Price-To-Sales -ratio ( 9.1 x) vergeleken met het German Biotechs -industriegemiddelde ( 12.6 x).

Wat is DOA's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

DOA is een goede waarde op basis van de Price-To-Sales -ratio ( 9.1 x) vergeleken met de geschatte eerlijke Price-To-Sales -ratio ( 12.9 x).

Wat is de reële prijs van DOA als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van DOA te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Soligenix (DB:DOA) - Aandelenkoers, Nieuws & Analyse

DOA Overzicht aandelen

A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Meer informatie

DOA fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 75.85% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 1.5% per jaar dalen.

Heeft geen betekenisvolle marktkapitalisatie ( €9M )

Heeft een omzet van minder dan 1 miljoen USD ( $949K )

Negatief eigen vermogen

+ 3 meer risico's

Soligenix, Inc. Concurrenten

Medigene

XTRA:MDG1

€20.6m

co.don

XTRA:CNW

€6.5m

Epigenomics

DB:ECX

€1.6m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Soligenix
Historische aandelenkoersen
Huidige aandelenkoers	US$5.85
52 Week Hoogtepunt	US$14.11
52 Week Laag	US$5.58
Bèta	1.74
11 maand verandering	0%
3 maanden verandering	-5.11%
1 Jaar Verandering	-10.53%
33 jaar verandering	-73.29%
5 jaar verandering	-71.94%
Verandering sinds IPO	-77.87%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	DOA	DE Biotechs	DE Markt
7D	0%	0.8%	0.8%
1Y	-10.5%	-18.3%	8.6%

Rendement versus industrie: DOA overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -18.3 % opleverde.

Rendement versus markt: DOA presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.6 % opleverde.

Prijsvolatiliteit

Is DOA's price volatile compared to industry and market?
DOA volatility
DOA Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: DOA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van DOA in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1987	14	Christopher Schaber	www.soligenix.com

Soligenix, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Soligenix zich tot de beurswaarde?
DOA fundamentele statistieken
Marktkapitalisatie	€7.89m
Inkomsten(TTM)	-€12.59m
Inkomsten(TTM)	€865.50k

9.1x

P/S-verhouding

-0.6x

Koers/Winstverhouding

Is DOA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DOA resultatenrekening (TTM)
Inkomsten	US$948.91k
Kosten van inkomsten	US$550.82k
Brutowinst	US$398.09k
Overige uitgaven	US$14.20m
Inkomsten	-US$13.80m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.45
Brutomarge	41.95%
Nettowinstmarge	-1,454.12%
Schuld/Eigen Vermogen Verhouding	-400.6%

Hoe presteerde DOA op de lange termijn?

Bekijk historische prestaties en vergelijking

DOA Overzicht aandelen

Beloningen

Risicoanalyse

Soligenix, Inc. Concurrenten

XTRA:MDG1

€20.6m

XTRA:CNW

€6.5m

DB:ECX

€1.6m

BST:BPXA

€772.4k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Recent updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Soligenix, Inc. Samenvatting

9.1x

-0.6x

Inkomsten en omzet